Johnson & Johnson (JNJ) Stock Forecast
Data as of Sep 17, 2026Healthcare · Current price $267.20 (—)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 15, 2026 | Rick Wise | Stifel Nicolaus | $250.00 | -6.4% |
| Apr 15, 2026 | Matt Miksic | Barclays | $255.00 | -4.6% |
| Jan 28, 2026 | Terrance Flynn | Morgan Stanley | $262.00 | -1.9% |
| Jan 27, 2026 | Ilya Zubkov | Loop Capital Markets | $220.00 | -17.7% |
| Jan 23, 2026 | Vamil Divan | Guggenheim | $240.00 | -10.2% |
| Jan 22, 2026 | Terence Flynn | Morgan Stanley | $200.00 | -25.1% |
| Jan 22, 2026 | Rick Wise | Stifel Nicolaus | $220.00 | -17.7% |
| Jan 22, 2026 | Asad Haider | Goldman Sachs | $250.00 | -6.4% |
| Jan 9, 2026 | Lee Hambright | Bernstein | $208.00 | -22.2% |
| Dec 30, 2025 | Matt Miksic | Barclays | $217.00 | -18.8% |
| Dec 18, 2025 | Asad Haider | Goldman Sachs | $240.00 | -10.2% |
| Oct 22, 2025 | Ilya Zubkov | Johnson Rice | $190.00 | -28.9% |
| Oct 15, 2025 | David Toung | Argus Research | $210.00 | -21.4% |
| Oct 15, 2025 | Terence Flynn | Morgan Stanley | $190.00 | -28.9% |
| Oct 10, 2025 | Shagun Singh | RBC Capital | $209.00 | -21.8% |
| Oct 3, 2025 | Larry Biegelsen | Wells Fargo | $212.00 | -20.7% |
| Apr 14, 2025 | Jayson Bedford | Raymond James | $162.00 | -39.4% |
| Feb 3, 2025 | Vamil Divan | Guggenheim | $166.00 | -37.9% |
| Oct 16, 2024 | Chris Shibutani | Goldman Sachs | $159.00 | -40.5% |
| Oct 16, 2024 | Terence Flynn | Morgan Stanley | $175.00 | -34.5% |
Top Analysts Covering JNJ
JNJ vs Sector & Market
| Metric | JNJ | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.14 | 2.26 | 2.42 |
| Analyst Count | 21 | 8 | 18 |
| Target Upside | +7.9% | +16187.2% | +19.5% |
| P/E Ratio | 30.89 | 3.81 | 38.28 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-28 | $100.62B | $100.79B | $101.07B | 17 |
| 2027-03-28 | $24.16B | $24.71B | $25.10B | 5 |
| 2027-03-29 | $24.75B | $25.07B | $25.41B | 5 |
| 2027-03-31 | $24.58B | $24.96B | $25.30B | 5 |
| 2027-06-28 | $25.63B | $26.21B | $26.62B | 5 |
| 2027-06-29 | $25.89B | $26.22B | $26.57B | 5 |
| 2027-06-30 | $25.83B | $26.22B | $26.58B | 5 |
| 2027-09-28 | $26.37B | $26.97B | $27.39B | 7 |
| 2027-09-29 | $26.60B | $26.94B | $27.30B | 8 |
| 2027-09-30 | $26.54B | $26.94B | $27.31B | 5 |
| 2027-12-28 | $104.40B | $107.42B | $109.13B | 18 |
| 2027-12-29 | $28.33B | $28.69B | $29.08B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-28 | $11.47 | $11.59 | $11.84 | 14 |
| 2027-03-28 | $2.87 | $2.95 | $3.01 | 5 |
| 2027-03-29 | $2.89 | $2.93 | $2.99 | 5 |
| 2027-03-31 | $2.88 | $2.93 | $2.99 | 4 |
| 2027-06-28 | $3.03 | $3.12 | $3.19 | 5 |
| 2027-06-29 | $3.05 | $3.10 | $3.15 | 5 |
| 2027-06-30 | $3.04 | $3.10 | $3.15 | 5 |
| 2027-09-28 | $3.14 | $3.23 | $3.30 | 5 |
| 2027-09-29 | $3.16 | $3.21 | $3.27 | 5 |
| 2027-09-30 | $3.15 | $3.21 | $3.27 | 8 |
| 2027-12-28 | $12.21 | $12.72 | $13.63 | 14 |
| 2027-12-29 | $3.26 | $3.31 | $3.37 | 5 |
Frequently Asked Questions
What is the analyst consensus for JNJ?
The consensus among 21 analysts covering Johnson & Johnson (JNJ) is Buy with an average price target of $286.93.
What is the highest price target for JNJ?
The highest price target for JNJ is $262.00, set by Terrance Flynn at Morgan Stanley on 2026-01-28.
What is the lowest price target for JNJ?
The lowest price target for JNJ is $90.00, set by John Ransom at Raymond James on 2023-05-24.
How many analysts cover JNJ?
21 analysts have issued ratings for Johnson & Johnson in the past 12 months.
Is JNJ a buy or sell right now?
Based on 21 analyst ratings, JNJ has a consensus rating of Buy (2.14/5) with a +7.9% upside to the consensus target of $286.93.
What are the earnings estimates for JNJ?
Analysts estimate JNJ will report EPS of $11.59 for the period ending 2026-12-28, with revenue estimated at $100.79B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.